MMA FREE Webinar Series - Psilocybin-assisted Therapy for End-of-Life Distress

Don’t miss out - Get your tickets early!

Join this FREE, 75-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Renewed interest in the therapeutic effects of psychedelics such as psilocybin has driven a rich array of academic research over the past two decades. In 2016 researchers at New York University (NYU) and John Hopkins University co-published two landmark studies reporting on the effects of a single dose of psilocybin-assisted therapy for the treatment of anxiety and depression associated with a cancer diagnosis. In the NYU study, Agin-Liebes et al (2020) found that at the 4.5 year follow-up 60–80% of participants continued to meet criteria for clinically significant antidepressant or anxiolytic responses. Participants overwhelmingly (71–100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives. These findings suggest that psilocybin-assisted psychotherapy can occasion spiritually salient experiences and holds promise in promoting long-term relief from cancer-related existential and psychiatric distress.

Dr. Gabby Agin-Liebes is a clinical psychologist and NIH-funded researcher at UC San Francisco. She was the lead investigator of the long-term follow-up study at NYU, which garnered media attention in several news outlets including Newsweek and CNN. In this presentation she will discuss:

• The unique existential challenges associated with a cancer diagnosis
• The study methodologies and findings of the primary (Ross et al., 2016) and long-term follow-up (Agin-Liebes et al., 2020) trials 
• Clinical implications of these study findings 
• The role of spiritually salient or mystical-type experiences in promoting relief from existential distress in cancer patients 
• Narrative/qualitative reports from participant interviews in the trial 
• Future directions of the research 

WEBINAR SESSION

Topic: Psilocybin-assisted Therapy for End-of-Life Distress

Date: Wednesday 28 April 2021

Time: 11:55am for 12:00pm start – 1:15pm (incl Q&A) (AEST)

The presentation WILL BEGIN AT 12:00pm.

Location: Online. A link will be emailed to you with the viewing details.

Don’t miss out - Get your tickets early!

Can't attend? You can still support MMA and ensure these treatments are available and accessible to those who are suffering!

Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.

More about Mind Medicine Australia and medicinal psychedelic-assisted therapy:

Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.

Unlike current treatments such as anti-depressants, which only manage the illness and can have nasty side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.

At Mind Medicine Australia we are dedicated to helping the now global movement to spread this awareness and ensure these medicines are available via the medical system. Please watch and share our 2 minute animation to find out why psychedelic-assisted psychotherapy needs to be available to those who are suffering.

More about the presenters:

Dr Gabby Agin-Liebes (USA)

Gabby Agin-Liebes, PhD is a clinical psychologist with 10 years of experience working as a therapist and investigator on academic trials with psilocybin-assisted therapy at New York University, Yale and UC San Francisco (UCSF). Her research has applied quantitative and qualitative methodologies within psilocybin-assisted and mindful self-compassion-based interventions to treat substance use and trauma-based disorders. She is currently a National Institutes of Health-funded research fellow at UCSF studying novel interventions for treating opioid addiction and chronic pain that target dysregulated emotion regulation and attentional bias processes. She is the lead author on a paper published earlier this year, and featured in several news outlets, which found that psilocybin-therapy led to sustained clinical remission from depression and anxiety in individuals with cancer up to 4.5 years later.

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.